1st Quarter - Report

JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2023 $630,000 Replaced
1st Quarter - Report Apr 20, 2023 $630,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies Provisions related to patient safety, CBD product regulations and FDA regulation and enforcement Drug safety, prescription drug abuse and drug pricing

LobbyistCovered position, as disclosed
KARAS GROSS —
VIRGINIA MCMILLIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.